Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVC-422 in adenoviral conjunctivitis
NCT01532336Phase 2Completed
- Sponsor
- NovaBay Pharmaceuticals, Inc.
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in adenoviral conjunctivitis comparing NVC-422 Solution, 0.3% with NVC-422 Vehicle Solution (2 arms). Primary endpoint: Sustained Clinical Cure at Day 18. Started May 2012; status: completed.
02
Drugs
auriclosene
03
Conditions
adenoviral conjunctivitis
Beyond the preview
Go deeper on NCT01532336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532336.